Outlook Therapeutics reports Q3 adjusted EPS (44c) vs. (83c) last year

Reports Q2 revenue $1.5M, consensus $1.66M. “With the first commercial sales of LYTENAVA in Europe for the treatment of wet AMD, the transformation of Outlook Therapeutics (OTLK) into a commercial company has begun,” commented Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “We are proud to report that the first patients have already been dosed in both Germany and the UK, and we are pushing ahead with our efforts to enhance the addition of this important therapy to the standard treatment regimen as quickly as possible in these key markets. We continue to execute on our commercial pathway forward and have preparations underway in advance of potential U.S. FDA approval later this month.”